The Crohn’s disease therapeutics pipeline is expected to witness extensive growth in the coming year due to emerging biosimilars and novel treatments. In addition, increasing number of pipeline drugs, rising demand for better medications, high prevalence of Crohn’s disease, involvement of the regulatory bodies for funding and designation and increase in the government agencies for the healthcare expenditure act as the major drivers for the Crohn’s disease therapeutics.
According to the Centre for Digestive Diseases, an Australian medical institution that collaborates with pharmaceutical companies to provide excellence in gastroenterology, Crohn’s disease is an inflammatory disease of the bowel that most commonly affects the lower small intestine and the large intestine, but can involve other parts of the digestive tract as well, from the mouth to the anus. Crohn’s disease causes inflammation of the entire thickness of the bowel wall that leads to the abdominal pain, diarrhea and a range of other symptoms such as fever and weight loss. The chances of its occurrence are equal for men and women and usually appears for the first time in patients above the age of 30 years with peak incidence in those aged 14-24 years. The etiology of Crohn’s disease is unknown. About 20% of people with Crohn’s Disease have a blood relative with some form of inflammatory bowel disease, most often a sibling and sometimes a parent or child. Smoking has also been observed as a factor contributing towards the development and exacerbation of Crohn’s Disease.
The pipeline of the Crohn’s disease therapeutics is very rich with 40+ drug candidates. Among them, Galapagos NV is developing filgotinib in collaboration with Gilead Sciences, Inc. for Crohn’s disease. Filgotinib is an orally administered, small molecule drug candidate that targets Janus kinase 1 and inhibits its action. A Phase III clinical development is going on in the U.S. and Belgium for the treatment of Crohn’s disease.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/crohns-disease-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of Crohn’s disease therapeutics include Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, Abbvie, Inc., Amgen, Inc., Pfizer, Inc., Tillotts Pharma AG, Johnson & Johnson, Takeda Pharmaceutical Company Ltd. and Boehringer Ingelheim GmbH.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)